These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 18285275

  • 1. Screening with the activated protein C resistance assay yields significant savings in a patient population with low prevalence of factor V leiden.
    Taylor LJ, Oster RA, Fritsma GA, Tichenor PH, Reed CE, Eiland BM, Hudson CL, Marques MB.
    Am J Clin Pathol; 2008 Mar; 129(3):494-9. PubMed ID: 18285275
    [Abstract] [Full Text] [Related]

  • 2. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
    Schöni R, Quehenberger P, Wu JR, Wilmer M.
    Thromb Res; 2007 Mar; 119(1):17-26. PubMed ID: 16934314
    [Abstract] [Full Text] [Related]

  • 3. A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
    De Bel AV, Van der Cruyssen GA, Devreese KM.
    Blood Coagul Fibrinolysis; 2006 Mar; 17(2):155-60. PubMed ID: 16479199
    [Abstract] [Full Text] [Related]

  • 4. Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction.
    Middendorf K, Göhring P, Huehns TY, Seidel D, Steinbeck G, Nikol S.
    Am Heart J; 2004 May; 147(5):897-904. PubMed ID: 15131548
    [Abstract] [Full Text] [Related]

  • 5. Prevalence of factor V Leiden mutation in Yugoslav thrombophilic patients and its relationship to the laboratory diagnosis of APC resistance.
    Mikovic D, Rakicevic L, Kovac M, Radojkovic D.
    Thromb Haemost; 2000 Oct; 84(4):723-4. PubMed ID: 11057877
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
    Montes MA, Fox EA, Longtine JA, Dorfman DM.
    Arch Pathol Lab Med; 1998 Apr; 122(4):325-9. PubMed ID: 9648899
    [Abstract] [Full Text] [Related]

  • 7. Activated protein C resistance and factor V Leiden in Mexico.
    Majluf-Cruz A, Moreno-Hernández M, Ruiz-de-Chávez-Ochoa A, Monroy-García R, Majluf-Cruz K, Guardado-Mendoza R, Molina-Avila I, Isordia-Salas I, Corona-de la Peña N, Vargas-Vorackova F, Vela-Ojeda J, García-Chávez J.
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):428-37. PubMed ID: 18160617
    [Abstract] [Full Text] [Related]

  • 8. [Diagnosis of thrombophilia based on coagulation and genetic studies].
    Bałszan-Kowalska I.
    Ann Acad Med Stetin; 2002 Oct; 48():179-93. PubMed ID: 14601477
    [Abstract] [Full Text] [Related]

  • 9. Estimating the cost of redundancy in molecular diagnostics: the case of activated protein C resistance and factor V Leiden.
    Rolla R, Vidali M, Meola S, Pollarolo P, Pergolini P, Bellomo G.
    Clin Lab; 2011 Oct; 57(9-10):711-7. PubMed ID: 22029186
    [Abstract] [Full Text] [Related]

  • 10. [National evaluation of the diagnosis of activated protein C resistance].
    Montiel-Manzano G, de la Peña-Díaz A, Majluf-Cruz A, Cesarman-Maus G, Corona-de la Peña N, Cruz-Cruz D, Gaminio E, Martínez-Murillo C, Mayagoitia T, Miranda-Peralta E, Poblete T, Quintana-Martínez S, Ramírez R, Razo D, Ruiz de Chávez-Ochoa A, Reyes-Núñez VA, Salazar R, Vicencio-Santiago GV, Villa R.
    Rev Invest Clin; 2003 Oct; 55(3):358-69. PubMed ID: 14515684
    [Abstract] [Full Text] [Related]

  • 11. Prevalence of factor V Leiden in the Chinese population.
    Ho CH, Chau WK, Hsu HC, Gau JP, Chih CM.
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Dec; 62(12):875-8. PubMed ID: 10634001
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Factor V Leiden and activated protein C resistance].
    Cauchie P, Hilbert P.
    Rev Med Brux; 1997 Jun; 18(3):97-102. PubMed ID: 9273603
    [Abstract] [Full Text] [Related]

  • 15. The effect of lupus anticoagulant in the second-generation assay for activated protein C resistance.
    Ragland BD, Reed CE, Eiland BM, Tichenor PH, Hudson CL, Fritsma GA, Adler BK, Marques MB.
    Am J Clin Pathol; 2003 Jan; 119(1):66-71. PubMed ID: 12520699
    [Abstract] [Full Text] [Related]

  • 16. Factor V Leiden mutation and type 1 diabetes mellitus.
    Demirer AN, Alikasifoglu M, Tuncbilek E, Karakus S, Erbas T.
    Blood Coagul Fibrinolysis; 2008 Jan; 19(1):70-4. PubMed ID: 18180619
    [Abstract] [Full Text] [Related]

  • 17. Comparison of Russell viper venom-based and activated partial thromboplastin time-based screening assays for resistance to activated protein C.
    Herskovits AZ, Lemire SJ, Longtine J, Dorfman DM.
    Am J Clin Pathol; 2008 Nov; 130(5):796-804. PubMed ID: 18854273
    [Abstract] [Full Text] [Related]

  • 18. Coagulation factor V Leiden mutation was detected in the patients with activated protein C resistance in Thailand.
    Arnutti P, Hiyoshi M, Prayoonwiwat W, Nathalang O, Suwanasophon C, Kokaseam R, Tatsumi N.
    Thromb Haemost; 1998 Aug; 80(2):344-5. PubMed ID: 9716166
    [No Abstract] [Full Text] [Related]

  • 19. A protein C pathway (PCP) screening test for the detection of APC resistance and protein C or S deficiencies.
    Haas FJ, van Sterkenburg-Kamp BM, Scheepers HA.
    Semin Thromb Hemost; 1998 Aug; 24(4):355-62. PubMed ID: 9763352
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of smoking as a risk factor for activated protein C resistance during pregnancy.
    Kafkas S, Kalkan U, Bolaman Z, Sanci M, Yüksel H, Odabaşi AR.
    Gynecol Obstet Invest; 2007 Aug; 64(2):89-94. PubMed ID: 17314487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.